Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ASCO 2022 | Bosutinib in newly diagnosed CML: GI, liver, effusion, and renal safety characterization

Jorge Cortes • 4 Jun 2022

ASCO 2022

Chronic Myeloid Leukemia Leukemia Bosutinib Imatinib

BFORE

Jorge Cortes, MD, Georgia Cancer Center, Augusta, GA, provides an overview of the gastrointestinal, liver, effusion, and renal safety characterization with the use of bosutinib in patients enrolled in the BFORE trial (NCT02130557). BFORE is a Phase III study evaluating the efficacy and safety of bosutinib versus imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML). The safety profiles of bosutinib and imatinib in BFORE were distinct, with no new safety signals identified after 5 years of follow-up. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Key emerging trials in CML and the importance of improving treatment-free remission rates

Jorge Cortes • 7 Sep 2023

Social determinants of health & their impact on patients with hematological malignancies

Jorge Cortes • 7 Sep 2023

Post-hoc analysis of OPTIC: patient responses to ponatinib by T315I mutational status

Jorge Cortes • 7 Sep 2023

Exciting updates in the field of CML: disease pathophysiology & novel agents

Jorge Cortes • 7 Sep 2023

Related Videos

The real-world safety and efficacy of CPX-351 in patients with AML

Priyanka Mehta • 22 Apr 2024

The pitfalls in genomics for myeloid malignancies

Thomas Coats • 29 Apr 2024

Should MRD eradication be the goal when treating every patient with CLL?

Dima El-Sharkawi • 28 Apr 2024

The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial

Felicitas Thol • 19 Apr 2024